Colon Cancer
description
Transcript of Colon Cancer
![Page 1: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/1.jpg)
Colon Cancer
![Page 2: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/2.jpg)
04/21/23 2
COLORECTAL CANCER
>140,000 new cases each yr in the US
3rd leading cause of death
It is curable if detected early
![Page 3: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/3.jpg)
04/21/23 3
HNPCC (Lynch syndrome)
Lynch I: No associated other cancers
Lynch II: Associated with ovarian, uterine cancers
+ ve Genetic test : Consider colectomy/TAH/BSO
![Page 4: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/4.jpg)
04/21/23 4
Familial adenomatous polyposis (FAP)
Autosomal-dominant 50% of pts will develop adenomas by age 15 and
95% by age 35. Left untreated, 100% of pts will develop
colorectal cancer. Invasive cancer occurs at ~ 42Y. The familial adenomatous polyposis coli (APC)
gene localized to chromosome 5q21.
![Page 5: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/5.jpg)
04/21/23 5
Genetic Tests
HNPCC COLARIS
FAP/AFAP COLARIS AP
![Page 6: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/6.jpg)
04/21/23 6
![Page 7: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/7.jpg)
04/21/23 7
Work-up
Laboratory: CBC, Iron profile LFTs CEA
Preoperative CT scan Colon cancer: Adjacent organ invasion/Liver met
![Page 8: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/8.jpg)
04/21/23 8
PET Scan
Staging Restaging
91% sensitivity, ~ 100% specificity for pelvic disease (CT: 52%, 80%)
95% sensitivity for liver disease (CT 74%)
![Page 9: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/9.jpg)
PET scan
NCCN: PET only as a pre-op baseline if CT/US
indicates potentially surgically curable M1. Characterization of extent of potentially
resectable disease
04/21/23 9
![Page 10: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/10.jpg)
Staging
Smooth metastatic nodules in pericolic or perirectal fat are considered LN mets (N1)
Irregular met nodules in peritumoral fat are considered vascular invasion
Minimum of 12 LN to accurately identify stage II
04/21/23 10
![Page 11: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/11.jpg)
04/21/23 11
TNM Stage I: T1 (invade submucosa) A
T2 (invade muscul propria) B1 Stage II: T3 (invade through musc propria B2
into subserosa or nonperit. Tissue)
T4 (perforate ves perit or B3 invade adjacent structure)
Stage III: N1 (1-3 pericolic/rectal) N2 (> 4) C
N3 (along vascular trunk)
Stage IV: M1
![Page 12: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/12.jpg)
04/21/23 12
5-Year Survival in CRC
Stage 5-Yr Survival rate (%)
I (A) 97
I (B1) 90
IIA (B2) 80
IIB (B3) 60
III (1-4 LN) 56
III (>4 LN) 26
IV 8
![Page 13: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/13.jpg)
![Page 14: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/14.jpg)
![Page 15: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/15.jpg)
Polyps Pedunculted polyp with invasive cancer (pT1):
single specimen + favorable features + clear margins Observe
Fragmented, unfavorable features, unclear margins Colectomy
Sessile polyp with invasive cancer (pT1): single specimen + favorable features + clear margin
Observe or colectomy Fragmented, unfavorable features, unclear margin
Colectomy
04/21/23 15
![Page 16: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/16.jpg)
Laparoscopic vs Conventional Colectomy
Barcelona trial (small trial): Modest survival advantage of laparoscopic
COLOR trial (1248 pts): 3Y DFS favor conventional
CLASSIC study (794 pt): No difference in DFS or OS
COST study (872 pt): No difference in 5Y recurrence, OS
Meta-analysis: No difference in local recurrence or OS
04/21/23 16
![Page 17: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/17.jpg)
Laparoscopic Colectomy: NOT RECOMMENDED in case of:
Tumor in lower and mid rectum Tumor acutely obstructed or
perforated T4 Adhesions
04/21/23 17
![Page 18: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/18.jpg)
04/21/23 18
Regional LN
Need at least 12 LN to accurately identify stage II colorectal cancer (AJCC and College of American Pathologists)
The number of +ve lymph nodes correlates with survival
At the present time the use of sentinel LN and detection of cancer cells by IHC alone should be considered investigational
![Page 19: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/19.jpg)
SLN Results are promising
No uniformity in the detection of true clinically relevant positive LN
It is investigational at the present time
04/21/23 19
![Page 20: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/20.jpg)
Positive margin
Presence of tumor within 1-2 mm from transected margin or within the diathermy margin
04/21/23 20
![Page 21: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/21.jpg)
Stage II-IIIAdj Therapy
04/21/23 21
![Page 22: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/22.jpg)
04/21/23 22
5-FU Thymidylate synthase inhibitors
Fluoropyrimidines
5 days IVP regimen: Mucositis, diarrhea, neutropenia
Wkly IVP regimen: Diarrhea
CI regimen: Hand-foot syndrome, mucositis Diarrhea or neutropenia
High dose regimen 24-48hrs Altered MS, angina-like chest pain
![Page 23: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/23.jpg)
04/21/23 23
New Drugs and Survival !!!
Capecitabine (Xeloda) Oxaliplatin Bevacizumab Cetuximab Panitumumab (Vectibix)
![Page 24: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/24.jpg)
Oxaliplatin-based Adj Therapy
MOSAIC trial (FOLFOX vs 5-FU/LV): 2246 pts with stage II and III 3, 4, and 6 yrs F/U
Stage III: 5Y DFS 66.4% vs 58.9% (P 0.005) Stage II: 5Y DFS not sig.
Analysis of individual pt data from 20,898 pts on 18 randomized colon adj trials:
OS of stage III treated with FOLFOX sig increased at 6Y f/u (78.5% vs 76%) hazard ratio=0.80; 95% CI, 0.65-0.97; P=0.023
04/21/23 24
![Page 25: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/25.jpg)
NSABP C-07 (bolus FLOX vs bolus FU/LV):
2407 pts with stage II, III 4Y DFS 73.6% vs 67% (P=0.0034)
04/21/23 25
![Page 26: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/26.jpg)
IRINOTECAN-based Adj therapy CALGB C89803:
Stage III colon ca IFL vs 5-FU/LV
No improvement in DFS or OS IFL: more neutropenia, fever, death
FOLFIRI: not superior to 5-FL/LV
04/21/23 26
![Page 27: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/27.jpg)
Oral Fluoropyrimidine (5-FU) derivatives
Capecitabine (Xeloda).
Tegafur (under investigated in Europe and US).
![Page 28: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/28.jpg)
•IV 5FU is the standard adjuvant therapy for CRC.
•Oral xeloda is at least as effective as IV 5FU in mCRC.
•Can Oral xeloda replace IV 5FU in adjuvant setting?
![Page 29: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/29.jpg)
Adjuvant Oral Adjuvant Oral
FluoropyrimidineFluoropyrimidine
Capecitabine (Xeloda) Capecitabine (Xeloda)
= =
IV 5-FU/LIV 5-FU/L
Conve
nient
![Page 30: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/30.jpg)
ANOTHER REASONANOTHER REASON
Tota
l Cos
t
![Page 31: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/31.jpg)
XELOX significantly improves DFS and RFS compared with 5-FU/LV
Trend to superior overall survival XELOX shows similar DFS benefit to
FOLFOX4 in a cross-trial comparison
With proven efficacy and a favourable safety profile, XELOX is a new standard
of care in the adjuvant treatment of early colon cancer
XELOX: a new standard of care
in the adjuvant setting
![Page 32: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/32.jpg)
Adj chemo for Stage II colon cancer Meta-analysis of 5 trials and practice-based
studies: Stage II and III treated with surgery +/- FU/LV
Most of benefits in stage III
Pooled data from 7 randomized trials: FU/LV sig improves OS in N+, Not in N0 colon ca
SEER databases: Stage II: Adj vs No Adj chemo 5Y OS 78% vs 75% not sig
QUASAR adj FU/LV: 3-4% OS benefit (small but sig)
04/21/23 32
![Page 33: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/33.jpg)
High Risk Stage II
G3-4 except MSI-H Lymphatic/vascular invasion Bowel obstruction Localized perforation Intermediate or positive margins < 12 LN examined Perineural invasion Oncotype DX (recurrence score >41)
04/21/23 33
![Page 34: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/34.jpg)
MicroSatellite Instability (MSI)
High MSI = deficient mismatch-repair phenotype (dMMR) = pood prognosis.
May not benefit from 5-FU, even could be harmful.
MMR testing for all pts < 50
04/21/23 34
![Page 35: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/35.jpg)
04/21/23 35
![Page 36: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/36.jpg)
Following surgery NCCN panel recommends
6 month of adj chemo for stage III (T1-4, N1-2, M0)
Options: FU/LV/Oxal (standard) or Capecitabine or FU/LV
No Irinotecan-based adj regimen 5-FU-based chemo for high risk stage II:
T4, G3-4, lymphovasc inv, BO, localized perforation, close or +ve margins, <12LN Subset from MOSAIC: No sig DFS benefit of FOLFOX
over FU/LV in stage II (but trend for improved DFS in high risk stage II receiving FOLFOX)
04/21/23 36
![Page 37: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/37.jpg)
Adj RT for colon cancer
Consider concurrent RT with 5-FU for:
T4 tumor penetrating into a fixed structure Locally recurrent disease
04/21/23 37
![Page 38: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/38.jpg)
Targeted therapies in
adjuvant setting.
![Page 39: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/39.jpg)
CONCLUSION Adjuvant Bevacizumab:
Did not prolong DFS Failed to improve the cure rate of patients
with resected colon cancer Did not reach the goal of eradicating
occult metastases
![Page 40: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/40.jpg)
04/21/23 40
SURVEILLANCE
H/P q 3 m for 2 y, then q 6 m for 3 y CEA q 3 m for 2 y, then q 6 m for 3 y Annual CT chest/abd/pelvis for high risk pts Colonoscopy in 1 y:
repeat in 1 y if abnormal
Then q 2-3 y If no preoperative colonoscopy:
colonoscopy in 3-6 mo.
![Page 41: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/41.jpg)
METASTATIC METASTATIC COLON COLON CANCERCANCER
04/21/23 41
![Page 42: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/42.jpg)
Oral Fluoropyrimidine for mCRC.
![Page 43: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/43.jpg)
ConclusionsXELOX
XELOX is non-inferior to FOLFOX
XELOX and FOLFOX safety profiles are balanced
XELOX offers the advantage of oral fluoropyrimidine administration
XELOX is a good alternative to FOLFOX
![Page 44: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/44.jpg)
Oral Fluoropyrimidine for Oral Fluoropyrimidine for
mCRC.mCRC.
Capecitabine (Xeloda) Capecitabine (Xeloda)
= =
IV 5-FU/LIV 5-FU/L
Conve
nient
![Page 45: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/45.jpg)
Targeted therapies in mCRC
![Page 46: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/46.jpg)
Bevacizumab (Avastin) (anti-VEGF)46
![Page 47: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/47.jpg)
Conclusions “Bevacizumab”
1st evidence from 1st line CRC phase III trial that bevacizumab adds
clinically meaningful statistically superior benefit to oxaliplatin-based chemotherapy
Safety profile overall in line with previous trial experience in colorectal cancer
The outcome of this trial adds to the large body of evidence supporting the use of bevacizumab in combination with standard 1st line chemotherapy
![Page 48: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/48.jpg)
Cetuximab (Cetuximab (ErbituxErbitux))
Panitumumab Panitumumab ((VectibixVectibix))
![Page 49: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/49.jpg)
OPUS-CRYSTAL Meta-Analysis
Addition of cetuximab to chemotherapy showed PFS benefit in patients with wild-type KRAS
With > 90% of samples collected, addition of cetuximab reduced risk of disease progression by 34% (HR: 0.66; P < .001)
OS results showed an advantage for patients with
wild‑type KRAS who received chemotherapy + cetuximab (HR: 0.81; P = .0062)
Van Cutsem E, et al. ECCO/ESMO 2009. Abstract P-6077. 04/21/23 49
![Page 50: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/50.jpg)
K-RAS, BRAF
K-RAS mutations in codon 12 or 13 in exon 2 predict lack of response to anti-EGFR drugs
Wild type K-RAS respond
Consider doing BRAF when K-RAS is non-mutated Wild type K-RAS and mutated BRAF
unlikely respond to ant-EGFR therapy
04/21/23 50
![Page 51: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/51.jpg)
Anti-EGFR + Anti-VEGF agents PACCE trial (chemo/Avastin+/-
Panitumumab) CAIRO2 trial (cape/Oxali/Avastin+/-
Erbitux) Decreased DFS Increases Toxicity
04/21/23 51
![Page 52: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/52.jpg)
Chemotherapy for advanced disease FULV +/- Avastin
MS 17.9 vs 14.6 m IFL +/- Avastin:
MS 20.3 vs 16.6 m (P<0.001) Phase III randomized N016966:
CapeOX vs FOLFOX CapeOX is not inferior to FOLFOX
Avastin only add 1.4 m to PFS and MS BICC-C study (phase III):
FOLFIRI is superior to mIFL or CapeIRI in efficacy and safety
FOLFIRI + Avastin vs mIFL + Avastin: MS 28 vs 19m
FOLFOX vs FOLFIRI: No diff in RR, PFS, OS FOLFOXIRI vs FOLFIRI:
One of 2 phase II showed improvement of DFS. FOLFOXIRI is more toxic 04/21/23 52
![Page 53: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/53.jpg)
Chemotherapy for advanced disease
CRYSTAL trial (FOLFIRI +/- Erbitux): Subset analysis for KRAS tumor status:
Sig improvement in M PFS (9.9 vs 8.7m ) if wild type gene
OPUS trial (FOLFOX +/- Erbitux): Improved RR
FOLFIRI, FOLFOX, CapeOX +/- Bevacizumab
FOLFIRI, FOLFOX +/-Cetuximab/Panitumumab
04/21/23 53
![Page 54: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/54.jpg)
Metastatic CRC Which Chemotherapy
First?
FOLFOX = FOLFIRI[1]
CapeOx = FOLFOX[2]
1. Tournigand C, et al. J Clin Oncol. 2004;22:229-237.2. Cassidy J, et al. J Clin Oncol. 2008;26:2006-2012.
04/21/23 54
![Page 55: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/55.jpg)
![Page 56: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/56.jpg)
Metastatic colon cancer
50-60% CRC pts will develop mets Synchronous liver mets: 15-25%
80-90% unresectable Intact tumor + synchronous mets:
Palliative resection is rarely indicated (acute obstruction and or significant bleeding)
Metachronous met is most common Mainly liver
04/21/23 56
![Page 57: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/57.jpg)
Liver mets
>50% of pts died of CRC have liver mets at autopsy
Liver met is cause of death in the majority In 30% liver as the only site of disease
Without surgery 5Y survival is very low In selected pts resection of liver mets could
lead to cure 5Y survival about 50%
04/21/23 57
![Page 58: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/58.jpg)
Resection of liver mets
Liver resection currently represents the only potentially curative therapeutic option for hepatic colorectal metastasis
5Y survival rates of 25% to 58% have been reported
04/21/23 58
![Page 59: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/59.jpg)
independent predictors of survival after
resection primary tumor stage Preoperative CEA hepatic tumor size number of hepatic metastases time from primary tumor treatment to
diagnosis of hepatic metastases presence of extrahepatic disease Status of surgical resection margin
Negative margins + maintaining adequate liver reserve
04/21/23 59
![Page 60: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/60.jpg)
Liver metsSurgical approach
Simultaneous resections of primary and synchronous liver mets
Preop portal vein embolization to increase the volume and function of remaining liver
Two stages of liver resection for bilobular disease
04/21/23 60
![Page 61: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/61.jpg)
Radiofrequency Ablation (RFA)
RFA is an option if surgery is not feasible
RFA is NOT a substitute to resection
RFA is inferior to resection with respect to rates of local recurrence and 5Y OS
04/21/23 61
![Page 62: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/62.jpg)
The goal of resection and or RFA is cure
Resection, RFA or combination “debulking” with goal less than complete resection/ablation of all known met sites is NOT RECOMMENDED.
04/21/23 62
![Page 63: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/63.jpg)
Preoperative chemo
Neoadjuvant: For resectable metastatic disease
Conversion chemo (downstaging): Liver-limited unresectable disease
04/21/23 63
![Page 64: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/64.jpg)
Preoperative chemo
Advantages: Treat micromets Chemo response Avoidance of local therapy
Disadvantages: Chemo-induced liver injury Missing the window of opportunity
Disease progression Achievement of complete response (difficult
to identify areas for resection) NCCN: Surgical eval 2 month after neoad and q
2m04/21/23 64
![Page 65: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/65.jpg)
Preoperative chemo
Study by Pozzo et al: Preop IFL in unresectable liver mets:
32.5% able to undergo rescetion Median time to progression: 14.3 months
NCCTG phase II: FOLFOX in 44 pts with unresectable liver mets
40% able to undergo resection
1439 pts with unresectable liver mets: 335 pts underwent primary liver resection 1104 pts received preop chemo:
138 good responders underwent resection 5Y OS = 33%
Intergroup N9741 phase III (retrospective): 795 pts underwent preop mostly Oxal-based chemo
24 pt able to undergo curative resection OS = 42.4 months
04/21/23 65
![Page 66: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/66.jpg)
Preoperative chemoWhat are the choices?
EORTC phase III: Initially resectable liver mets periop FOLFOX 6 cycles before and after
surgery vs surgery alone) Absolute improvement in 3Y PFS of 8.1%
(P=0.041) and 9.2% (p=0.025) for all eligible and all resected pts repectively.
Chemo options: FOLFIRI, FOLFOX, CapeOX +/- Bevacizumab FOLFIRI, FOLFOX
+/-Cetuximab/Panitumumab04/21/23 66
![Page 67: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/67.jpg)
Is Bevacizumab safe in the perioperative
setting? Two retrospective randomized trials (1,132 pts): Increased wound healing complications for pts
undergoing major surgery while receiving Avastin 13 vs 3.4% P=0.28
Preop chemo +/- Avastin: Wound healing complications in either group was
low (1.3% vs 0.5% P=0.63)
04/21/23 67
NCCN recommends: *at least 6 wks from last dose of Avastin before elective surgery.*6-8 wks post-op before resuming Avastin
![Page 68: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/68.jpg)
Preop chemo and hepatotoxicity
Irinotecan: Steatohepatitis
Oxaliplatin: Sinusoidal liver injury
Surgery should be berformed ASAP after the pt becomes resectable
04/21/23 68
![Page 69: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/69.jpg)
Extra-hepatic mets
Lung: Most of treatment recommendations for
hepatic mets applicable for pulmonary mets
Abdominal/peritoneal mets: Treatment is palliative
04/21/23 69
![Page 70: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/70.jpg)
Adj chemo following curative resection of liver
or lung mets Not enough data Pooled analysis from 2 randomized trials:
FU/LV vs observation: Median PFS: 27.9m vs 18.8m (P=0.058) No diff in OS
04/21/23 70
NCCN: Recommends active chemo for total of 6 months of perioperative time
![Page 71: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/71.jpg)
Hepatic Artery implantable pump (HAI)
Done during hepatic resection Adj floxuridine + dexam by HAI +/-
systemic chemo: 2Y survival and time to progression favor
HAI No diff in OS
04/21/23 71
![Page 72: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/72.jpg)
Liver-directed therapy
Arterial radioembolization with yttrium-90 microspheres
Arterial chemoembolization Conformal RT
04/21/23 72
![Page 73: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/73.jpg)
Synchronous unresectable Liver and lung mets
Palliative resection of primary: acute obstruction significant bleeding
Chemo options: FOLFIRI, FOLFOX, CapeOX +/- Bevacizumab
or Cetuximab Intact tumor is NOT a contra-indication to
Avastin Debulking surgery may be a risk factor for
bowel perforation when treat with Avastin04/21/23 73
![Page 74: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/74.jpg)
Synchronous Abd/Peritoneal mets
If Obstructive: Colon resection, diverting colostomy,
bypass, stenting Then chemotherapy
Carcinomatosis Cytoreductive (peritoneal stripping) – in
clinical trial Perioperative hyperthermic IP chemo - in
clinical trial
04/21/23 74
![Page 75: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/75.jpg)
Metachronous mets
Resectable: Resection followed by chemo X 6 m or Neoadj chemo x 2-3 m resection
chemo for total of 6 m peri-op chemo Unresectable:
Chemo based on prior chemo E.g.; Progression on FOLFOX within 12m,
switch to FOLFIRI)
04/21/23 75
![Page 76: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/76.jpg)
How to Predict and
Avoid Toxicity
?04/21/23 76
![Page 77: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/77.jpg)
Oxaliplatin Neurotoxicity OPTIMOX1 (Stop-and-Go approach) :
FOLFOX x6 FULV reintroduce Oxali upon progression
Decreased toxicity, did not affect survival
OPTIMOX2: OPTIMOX1 vs FOLFOX x6 Stop reintroduce FOLFOX
upon progression
MOS 26 vs 19 m (P=0.0549)
04/21/23 77
NCCN:*Consider D/C Oxali from FOLFOX/CapeOx after 3m or sooner for unacceptable neurotoxicity, with other drugs maintaned until progression.*Oxali should not be reintroduced unless near-total resolution of neurotoxicity*Infusion of Ca and Mg may limit neurotoxicity
![Page 78: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/78.jpg)
5-FU DihydroPyrimidine Dehydrogenase deficincy (DPD) Thymidylate Synthase (TYMS/TS) mutation
associated with reduced TS production and subsequent 5-FU toxicity
TheraGuide 5-FU: TYMS and DPYD genes mutation
25% of pts have them 60% risk of severe or life threatening toxicity
OnDose (target range AUC of 20-24mg.hr/L) To optimize dosing of 5-FU To reduce 5-FU toxicity do test at any time after 2 hr of C. I. 5FU
04/21/23 78
![Page 79: Colon Cancer](https://reader035.fdocuments.us/reader035/viewer/2022062518/5681472e550346895db46b3b/html5/thumbnails/79.jpg)
Irinotecan
Due to accumulation of active metabolite (SN-38) in the intestine
SN-38 metabolized by UGT1A1 UGT1A1 *28 allele associated with
reduced UGT1A1 expression
04/21/23 79